AGIOS PHARMACEUTICALS, INC. Current Federal Tax Expense (Benefit)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Current Federal Tax Expense (Benefit) of -$444.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-16.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2017-02-16
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for the quarter ending 2014-12-31 was $4.00K.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for the quarter ending 2014-09-30 was -$448.00K, a 470.25% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for the quarter ending 2013-12-31 was -$3.67M.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for the quarter ending 2013-09-30 was $121.00K.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2014 was -$444.00K.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2013 was -$3.26M.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2012 was -$9.53M, a 166.16% decline from fiscal 2011.
- AGIOS PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2011 was $14.41M.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$444.00K derived: sum of 2 quarters · filed 2017-02-16 | -$444.00K 10-K · filed 2017-02-16 | |
| 2014-09-30 | -$448.00K 10-Q · filed 2014-11-07 | -$448.00K 10-Q · filed 2014-11-07 | ||
| 2013-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$3.55M derived: sum of 2 quarters · filed 2016-02-26 | -$3.45M derived: sum of 3 quarters · filed 2016-02-26 | -$3.26M 10-K · filed 2016-02-26 |
| 2013-09-30 | $121.00K 10-Q · filed 2014-11-07 | $220.00K derived: sum of 2 quarters · filed 2014-11-07 | $410.00K 10-Q · filed 2014-11-07 | -$2.68M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $99.00K 10-Q · filed 2014-08-07 | $289.00K 10-Q · filed 2014-08-07 | -$2.81M derived: sum of 3 quarters · filed 2015-02-24 | -$4.73M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $190.00K 10-Q · filed 2014-05-09 | -$2.90M derived: sum of 2 quarters · filed 2015-02-24 | -$4.83M derived: sum of 3 quarters · filed 2015-02-24 | -$7.20M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | -$3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$5.02M derived: sum of 2 quarters · filed 2015-02-24 | -$7.39M derived: sum of 3 quarters · filed 2015-02-24 | -$9.53M 10-K · filed 2015-02-24 |
| 2012-09-30 | -$1.92M 10-Q · filed 2013-11-07 | -$4.30M derived: sum of 2 quarters · filed 2013-11-07 | -$6.44M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | -$2.37M 10-Q · filed 2013-09-05 | -$4.51M 10-Q · filed 2013-09-05 | ||
| 2011-12-31 | $14.41M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |